Last reviewed · How we verify
NCT01253122
Comparative Bioavailability of TRx0037 and TRx0014 in Healthy Elderly Volunteers
Phase 1 trial testing TRx0037 in Alzheimer's Disease in 24 participants. Completed in 1 April 2010.
1 April 2010
Quick facts
| Lead sponsor | TauRx Therapeutics Ltd |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 24 |
| Start date | 1 February 2010 |
| Primary completion | 1 April 2010 |
| Estimated completion | 1 April 2010 |
Drugs / interventions tested
- TRx0037 — full drug profile →
Conditions studied
- Alzheimer's Disease — all drugs for Alzheimer's Disease →
Sponsor
TauRx Therapeutics Ltd — full company profile →
Who can join
55 and older, any sex, with Alzheimer's Disease. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Relative bioavailability
Investigate the relative bioavailability of TRx0037 and TRx0014 at two molar equivalent doses in healthy elderly male and female (post-menopausal/non-childbearing) subjects
Sponsor's own description
A randomised four way crossover design in which each subject will receive two dose levels of TRx-0037 and two doses of TRx-0014 over approximately a four week period in randomised order.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01253122
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Alzheimer's Disease
Currently open trials in the same condition.
- NCT07457138 — Lombard Cohort of Brain Health Services · recruiting
- NCT07234942 — A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants Wit · Phase 1 · recruiting
- NCT07479914 — Art of Memory for Cognitive Enhancement in the Monza Brain Health Service · NA · active not recruiting
- NCT07214727 — A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease · Phase 1 · recruiting
- NCT07105709 — Open-label Extension Study in Participants With Early Alzheimer's Disease · Phase 2 · recruiting
Other TauRx Therapeutics Ltd trials
Trials by the same sponsor.
- NCT03446001 — Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment · Phase 3 · completed
- NCT00684944 — Open Label Study of TRx0014 in Alzheimer's Disease · Phase 2 · completed
- NCT03539380 — TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease · available
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01253122 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by TauRx Therapeutics Ltd
- Last refreshed: 2 December 2010
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01253122.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing